Wockhardt has informed that it enclosed a Press Release titled ‘National Institutes of Health (NIH), USA to conduct human Phase 1 trial of Wockhardt’s novel once-a-day MDR Gram-negative antibiotic WCK 6777’.
The above information is a part of company’s filings submitted to BSE.